Peptide News Digest

#Peptide-Development-Labs

1 story

Industry · View digest

Peptide Development Labs, Which Is Developing an Injectable BPC-157 Drug Candidate, Raises $3 Million Ahead of Its Canadian Listing

Peptide Development Labs, spun out of HYTN Innovations, closed a private placement of 6 million units at 50 cents each for about $3 million and expects its shares to start trading on the Canadian Securities Exchange under the symbol PEPT on November 20. The company says its lead program is an investigational injectable BPC-157 drug candidate for refractory ligament disorders, which it plans to advance through established regulatory pathways. The release names no trial, regulatory filing, or timeline.